Nisa Investment Advisors LLC Cuts Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Nisa Investment Advisors LLC cut its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 9.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,634 shares of the medical research company’s stock after selling 771 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Charles River Laboratories International were worth $1,805,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. VisionPoint Advisory Group LLC increased its holdings in shares of Charles River Laboratories International by 105.7% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 74 shares during the period. Covestor Ltd grew its stake in Charles River Laboratories International by 100.0% during the 1st quarter. Covestor Ltd now owns 174 shares of the medical research company’s stock worth $49,000 after buying an additional 87 shares during the last quarter. Headlands Technologies LLC purchased a new position in Charles River Laboratories International during the 3rd quarter worth $37,000. Operose Advisors LLC purchased a new position in Charles River Laboratories International during the 3rd quarter worth $42,000. Finally, Salem Investment Counselors Inc. grew its stake in Charles River Laboratories International by 65.5% during the 2nd quarter. Salem Investment Counselors Inc. now owns 240 shares of the medical research company’s stock worth $51,000 after buying an additional 95 shares during the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on CRL shares. Evercore ISI boosted their target price on Charles River Laboratories International from $260.00 to $265.00 and gave the stock an “outperform” rating in a research note on Thursday, February 15th. UBS Group boosted their target price on Charles River Laboratories International from $270.00 to $290.00 and gave the stock a “buy” rating in a research note on Thursday, February 15th. TheStreet upgraded Charles River Laboratories International from a “c+” rating to a “b-” rating in a research note on Friday, March 1st. Argus boosted their target price on Charles River Laboratories International from $240.00 to $290.00 and gave the stock a “buy” rating in a research note on Monday, March 18th. Finally, Robert W. Baird boosted their price target on Charles River Laboratories International from $252.00 to $268.00 and gave the company an “outperform” rating in a research note on Thursday, February 15th. Five investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $253.23.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Victoria L. Creamer sold 5,000 shares of the stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $253.70, for a total transaction of $1,268,500.00. Following the transaction, the executive vice president now owns 13,550 shares in the company, valued at $3,437,635. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Charles River Laboratories International news, EVP Victoria L. Creamer sold 5,000 shares of the stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $253.70, for a total transaction of $1,268,500.00. Following the transaction, the executive vice president now owns 13,550 shares in the company, valued at $3,437,635. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Shannon M. Parisotto sold 5,882 shares of the stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total value of $1,418,738.40. Following the transaction, the executive vice president now owns 2,596 shares in the company, valued at approximately $626,155.20. The disclosure for this sale can be found here. Insiders have sold a total of 14,932 shares of company stock valued at $3,693,663 over the last ninety days. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Down 2.1 %

Charles River Laboratories International stock opened at $241.34 on Friday. The firm has a market cap of $12.43 billion, a price-to-earnings ratio of 26.20, a price-to-earnings-growth ratio of 1.93 and a beta of 1.40. Charles River Laboratories International, Inc. has a 52 week low of $161.65 and a 52 week high of $275.00. The business’s 50-day moving average price is $252.64 and its 200 day moving average price is $220.13. The company has a quick ratio of 1.16, a current ratio of 1.52 and a debt-to-equity ratio of 0.73.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, February 14th. The medical research company reported $2.46 EPS for the quarter, topping the consensus estimate of $2.39 by $0.07. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $991.25 million. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. Charles River Laboratories International’s revenue for the quarter was down 7.9% compared to the same quarter last year. During the same period last year, the company earned $2.98 earnings per share. As a group, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).